Mineralys Therapeutics, Inc. (MLYS)
(Delayed Data from NSDQ)
$11.76 USD
+0.17 (1.47%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $11.74 -0.02 (-0.17%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Cash flow Statements
Fiscal Year End for Mineralys Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -71.90 | -29.80 | -19.41 | -3.43 | NA |
Depreciation/Amortization & Depletion | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Change from Assets/Liabilities | -7.47 | 0.77 | 4.09 | 0.48 | NA |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Operating Activities | -1.81 | -0.19 | 0.76 | 0.48 | NA |
Net Cash From Operating Activities | -81.17 | -29.22 | -14.56 | -2.46 | NA |
Property & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Investments | -160.47 | -21.76 | 0.00 | 0.00 | NA |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Cash from Investing Activities | -160.47 | -21.76 | 0.00 | 0.00 | NA |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 203.18 | 129.65 | 23.81 | -0.02 | NA |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 3.85 | NA |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Financing Activities | 0.06 | -1.63 | 0.00 | 0.00 | NA |
Net Cash from Financing Activities | 203.25 | 128.02 | 23.81 | 3.83 | NA |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Change In Cash & Equivalents | -38.40 | 77.04 | 9.25 | 1.37 | NA |
Cash at Beginning of Period | 87.70 | 10.66 | 1.41 | 0.04 | NA |
Cash at End of Period | 49.30 | 87.70 | 10.66 | 1.41 | NA |
Diluted Net EPS | -1.99 | -5.77 | -3.89 | NA | NA |
Fiscal Year End for Mineralys Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -72.52 | -31.51 | -71.90 | -47.51 | -24.75 |
Depreciation/Amortization & Depletion | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 |
Net Change from Assets/Liabilities | 23.51 | 12.68 | -7.47 | -3.49 | -7.60 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | -0.29 | -0.32 | -1.81 | -1.20 | -0.81 |
Net Cash From Operating Activities | -49.29 | -19.14 | -81.17 | -52.19 | -33.16 |
Property & Equipment | -0.06 | -0.06 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -48.16 | -55.89 | -160.47 | -152.38 | -156.39 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -48.22 | -55.95 | -160.47 | -152.38 | -156.39 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 116.26 | 116.27 | 203.18 | 203.17 | 202.99 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.21 | -0.06 | 0.06 | 0.00 | 0.00 |
Net Cash from Financing Activities | 116.05 | 116.21 | 203.25 | 203.17 | 202.99 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 18.55 | 41.11 | -38.40 | -1.40 | 13.44 |
Cash at Beginning of Period | 49.30 | 49.30 | 87.70 | 87.70 | 87.70 |
Cash at End of Period | 67.86 | 90.42 | 49.30 | 86.30 | 101.14 |
Diluted Net EPS | -0.83 | -0.70 | -0.60 | -0.57 | -0.31 |